DM Kendall, MC Riddle, J Rosenstock, D … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—Week 30 A1C changes from baseline (±SE) were −0.8 ± 0.1% (10 μg),
−0.6 ± 0.1% (5 μg), and +0.2 ± 0.1% (placebo; adjusted P < 0.0001 vs.
placebo), yielding placebo-adjusted reductions of −1.0% (10 μg) and ... Cited by 542 - Related articles - All 11 versions
- ►shouxi.net IB Hirsch - The New England journal of medicine, 2005 - nejm.highwire.org By the early 1980s, the development of purified pork insulin and then
recombinant human insulin virtually eliminated insulin allergy and
immune-mediated lipoatrophy. These achievements marked a slowdown in the ... Cited by 334 - Related articles - All 6 versions
- ►annals.org [PDF] RJ Heine, LF Van Gaal, D Johns, MJ Mihm, … - Annals of internal medicine, 2005 - Am Coll Physicians Patients: 551 patients with type 2 diabetes and inadequate gly- cemic control
(defined as hemoglobin A1c level ranging from 7.0% to 10.0%) despite combination
metformin and sulfonylurea therapy. Intervention: Exenatide, 10 g twice ... Cited by 329 - Related articles - BL Direct - All 7 versions
P Raskin, E Allen, P Hollander, A Lewin, RA … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—A total of 209 subjects completed the study. At study end, the mean
HbA 1c value was lower in the BIAsp 70/30 group than in the glargine group (6.91
± 1.17 vs. 7.41 ± 1.24%, P < 0.01). The HbA 1c reduction was greater in ... Cited by 323 - Related articles - All 7 versions
- ►annals.org [PDF] J Rosenstock, B Zinman, LJ Murphy, SC … - Annals of internal medicine, 2005 - Am Coll Physicians Inhaled Insulin Improves Glycemic Control When Substituted for or ... Added to
Oral Combination Therapy in Type 2 Diabetes ... Julio Rosenstock, MD; Bernard
Zinman, MD; Liam J. Murphy, MD; Stephen C. Clement, MD; Paul Moore, MD; C. ... Cited by 163 - Related articles - BL Direct - All 8 versions
- ►shouxi.net PE Cryer - New England Journal of Medicine, 2004 - content.nejm.org In this article, I discuss the clinical problem of hypoglycemia in diabetes from
the perspective of pathophysiology. First, the syndromes of defective glucose
counterregulation and hypoglycemia without warning symptoms (known as " ... Cited by 153 - Related articles - BL Direct - All 6 versions
AJ Garber, J Wahlen, T Wahl, P Bressler, R … - Diabetes Obesity and Metabolism, 2006 - epgonline.com Methods: Enrolled patients (n ¼ 100, HbA1c !7.5 and 10%) were !18 years of age,
had diabetes !12 months and had received a stable antidiabetic regimen for at
least 3 months [minimum of two oral antidiabetic drugs (OADs) or at least ... Cited by 141 - Related articles - View as HTML - BL Direct - All 10 versions
- ►pipex.com [PDF] RR Holman, KI Thorne, AJ Farmer, MJ Davies, … - New England Journal of Medicine, 2007 - content.nejm.org From the Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and
Metabolism (RRH, KIT, AJF, JFK, SP, JCL) and the Department of Primary Health
Care (AJF), University of Oxford, Oxford; and the Department of Cardiovas- ... Cited by 133 - Related articles - BL Direct - All 12 versions
G Dailey, J Rosenstock, RG Moses, K Ways - Diabetes care, 2004 - Am Diabetes Assoc RESULTS—A slightly greater reduction from baseline to end point of HbA 1c was
seen in the glulisine group versus RHI (−0.46 vs. −0.30% with RHI; P =
0.0029). Also, at end point, lower postbreakfast (156 vs. 162 mg/dl [8.66 ... Cited by 104 - Related articles - BL Direct - All 7 versions
J Rosenstock, D Sugimoto, P Strange, JA … - Diabetes Care, 2006 - Am Diabetes Assoc RESULTS—A1C improvements from baseline were similar in both groups (−1.7 vs.
−1.5% for insulin glargine vs. rosiglitazone, respectively); however, when
baseline A1C was >9.5%, the reduction of A1C with insulin glargine was ... Cited by 100 - Related articles - BL Direct - All 8 versions
